Updates on the Treatment of Erythrodermic Psoriasis (Abstract)

Updates on the Treatment of Erythrodermic Psoriasis

Dovepress
09 June 2021
https://www.dovepress.com/getfile.php?fileID=70334

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP, including Naltrexone, which affects the opioid growth factor-opioid growth factor receptor, also plays a role in the immune system. Beltran Monasterio et al reported after oral low-dose naltrexone with a daily dose of 4.5 mg for 3 months, the patient remained complete remission after 6 months of treatment.

Keywords: erythrodermic psoriasis, treatment